Table 2 Frequency of the investigated cell surface and intracellular markers
Non-pregnant women (n = 14) | Healthy pregnant women (n = 20) | |
|---|---|---|
CD3+ CD28+ cells/CD3+ lymphocytes | 76.0 (64.7-82.9)% | 88.4* (81.8-90.6)% |
CD3+ CD28+ CD152+ cells/CD3+ CD28+ lymphocytes | 8.90 (7.57-11.4)% | 6.64* (5.07-9.89)% |
CD3+ CD278+ cells/CD3+ lymphocytes | 55.7 (49.5-56.7)% | 89.9* (75.7-91.6)% |
CD3+ CD279+ cells/CD3+ lymphocytes | 46.3 (39.3-51.2)% | 51.9* (47.9-67.7)% |
CD4+ CD28+ cells/CD4+ lymphocytes | 97.8 (96.7-98.8)% | 97.3 (93.0-99.2)% |
CD4+ CD28+ CD152+ cells/CD4+ CD28+ lymphocytes | 6.92 (4.93-8.63)% | 5.61 (3.65-9.09)% |
CD4+ CD278+ cells/CD4+ lymphocytes | 56.7 (52.8-59.5)% | 87.7* (76.3-92.2)% |
CD4+ CD279+ cells/CD4+ lymphocytes | 49.4 (42.1-54.5)% | 44.2 (37.5-65.2)% |
CD11b + CD80+ cells/CD11b + monocytes | 55.5 (17.3-69.8)% | 17.6* (13.6-25.4)% |
CD11b + CD86+ cells/CD11b + monocytes | 23.8 (17.3-29.5)% | 20.7 (14.9-31.9)% |
CD11b + CD274+ cells/CD11b + monocytes | 78.4 (70.3-85.9)% | 80.7 (77.2-87.8)% |
CD11b + CD275+ cells/CD11b + monocytes | 63.8 (59.0-72.1)% | 17.3* (14.1-27.0)% |
CD3+ IDO + cells/CD3+ lymphocytes | 5.90 (2.65-16.9)% | 24.1* (13.3-56.4)% |
IDO mean fluorescence intensity in CD3+ IDO + cells (arbitrary unit) | 9888 (7482–11475) | 62500* (19800–84475) |
CD11b + IDO + cells/CD11b + monocytes | 2.59 (1.99-11.7)% | 22.5* (13.6-50.5)% |
IDO mean fluorescence intensity in CD11b + IDO + cells (arbitrary unit) | 21400 (19075–23875) | 70450* (38775–114000) |